Hong Kong – Kaisa Health Group Holdings Limited reported a consolidated loss attributable to shareholders of HK$46.68 million for the year ended 31 December 2025, marginally higher than the HK$46.36 million loss a year earlier. Basic loss per share was 0.93 Hong Kong cents.
Revenue fell 25.0% to HK$139.11 million (FY2024: HK$185.36 million) as average selling prices for dental products declined under mainland China’s centralised procurement policy. Gross profit slid 38.2% to HK$50.64 million, compressing gross margin to 36.4% from 44.2%.
Segment performance diverged sharply: • Dental Business revenue contracted 26.2% to HK$132.03 million and posted a pre-tax loss of HK$44.52 million (FY2024 pre-tax profit: HK$9.82 million). • Health Care Business revenue grew 11.0% to HK$7.08 million and recorded a pre-tax profit of HK$7.78 million, reversing the FY2024 loss of HK$13.95 million.
Cost dynamics • Selling and distribution expenses rose 7.5% to HK$51.18 million, reflecting higher marketing outlays. • Administrative expenses fell 23.7% to HK$35.09 million due to lower staff costs and efficiency gains. • Research and development spending increased 35.5% to HK$16.91 million. • Net impairment on receivables narrowed to HK$5.96 million from HK$19.08 million.
Fair-value movements on financial assets at FVTPL generated a HK$10.56 million gain (FY2024 loss: HK$9.77 million), mainly from the Group’s 5.51% interest in Zhuhai Jinyiming Equity Investment Fund Partnership (L.P.) and its 99.9% limited-partner stake in Haoyi Healthcare Services (Shenzhen) Partnership (L.P.). At year-end these investments were valued at HK$162.24 million, equal to 34.4% of total assets.
Balance-sheet highlights • Bank balances and cash: HK$109.60 million (31 December 2024: HK$149.61 million). • Net current assets: HK$192.54 million. • Net assets: HK$398.50 million versus HK$426.49 million a year earlier. • Capital expenditure rose to HK$21.18 million, primarily for production equipment and right-of-use assets. The Group remained debt-free, with only HK$1.49 million in amounts due to related parties, all interest-free and repayable on demand.
The Board declared no dividend for FY2025.
Post-balance-sheet events On 18 March 2026 the company announced: 1) A proposed 50-for-1 share consolidation, subject to shareholder approval; 2) An agreement to acquire Embrace Blossom Limited from Profit Vigorous Developments Limited (a wholly-owned subsidiary of Kaisa Group) for RMB21.60 million (approximately HK$24.41 million), to be settled entirely by new share issuance.
No other material events were reported after year-end.